GNI Group Ltd.(2160) News

Disclosure of Statements Made at an Investor Conference of Gyre Therapeutics, Inc.

(Correction) Notice Regarding Differences in Non-Consolidated Financial Results

(Correction of Numerical Data) Partial Correction to the“Consolidated Financial Results for FY 2025 (IFRS)”

Notice Concerning Appointment of Directors

Notice Regarding the Execution of an Agreement for the Acquisition of Cullgen Inc. by Consolidated Subsidiary Gyre Therapeutics, Inc.

Notice Regarding the Postponement of the Disclosure of FY2026 Consolidated Earnings Forecast and Earnings Briefing

Consolidated Financial Results for FY2025 (IFRS)

Notice Regarding Differences in Non-Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 and the Previous Fiscal Year

Questions from Investors and Answers

Announcement Regarding Revision of Full-Year Earnings Forecast and Expected Recognition of Losses

Notice Concerning Completion of Acquisition of Shares (Conversion into a Consolidated Subsidiary) of ZOO LABO, Inc.

Cullgen’s Participation in the J.P. Morgan Healthcare Conference

Notice Regarding Completion of the Pre-NDA Meeting on the Regulatory Strategy for F351 Following Potential Eligibility for Priority Review

Notice Concerning Change in Consolidated Subsidiary (Termination of Equity Relationship)

Partial Amendment to Contractual Terms Relating to the Reverse Merger Transaction by Major Subsidiary Cullgen

Completion of Phase 1 Clinical Trial and Positive Results of CG001419, a Novel Non-Opioid Pain Product Candidate Developed by Key Subsidiary Cullgen

Q3 FY2025 Financial Results Corporate Presentation

Consolidated Financial Results for Q3 FY2025 YTD (IFRS)

Notice of Completion of Subject Enrollment in the Phase 3 Clinical Trial of Pirfenidone Capsule for the Treatment of Pneumoconiosis

Notice of Phase 3 Trial Results of F351 (Hydronidone) at AASLD-The Liver Meeting 2025